The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Tomonori Mizutani
Honoraria - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca; Chugai Pharma
Other Relationship - Pfizer.Inc
 
Yuta Sekino
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - Asahi Kasei; AstraZeneca; Chugai Pharma; MSD
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst)
 
Noriko Yanagitani
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Chugai Pharma; Pfizer
 
Hiroki Izumi
Honoraria - Bristol-Myers Squibb Japan; Chugai/Roche; Lilly; Merck; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyowa Kirin International; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Tatsuro Fukuhara
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
 
Yuka Fujita
Research Funding - Asahi Kasei (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst)
 
Toshiaki Takahashi
Honoraria - Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD K.K.; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K. (Inst); Pfizer (Inst)
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; CMIC Co., Ltd.; Kyowa Kirin Co., Ltd.; m3.com
 
Yuichiro Ohe
Leadership - JCOG; JSMO
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; PharmaMar; PharmaMar; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)